HomePipeline

6 molecules
1 receptor family

PNB Vesper's pipeline comprises six patented new chemical entities (NCEs), all derived from its proprietary cholecystokinin (CCK) receptor platform. Two molecules are currently in clinical development with 6 indications, while four have successfully completed preclinical studies and ready for Regulatory IND studies

New chemical entities
6
In clinical trials
2
Molecule–indication programmes
14
Therapeutic areas
4

Programme highlights.

Where PNB Vesper's main programmes stand today.

  1. 01

    Ulcerative Colitis and Crohn's Disease

    View the indication
    • Phase II clinical trials completed for both indications with significant results.
    • Phase III clinical trial application for Ulcerative Colitis submitted to DCGI.
  2. 02

    Diabetes Mellitus

    View the indication
    • Phase II clinical trial application submitted to DCGI; provisional approval received, awaiting final approval.
    • Novel mechanism of action with disease-modifying effects. First in class.
  3. 03

    Cocaine and Opioid Addiction Disorders

    View the indication
    • Collaboration with the US Government's NIH / NIDA, covering Cocaine Addiction, Opioid Addiction and Substance Use Disorders.
    • Cocaine Addiction studies completed by the National Institute on Drug Abuse, USA, with significant results.
    • Confirmatory opioid efficacy studies ongoing with NIH / NIDA.
    • Advancing towards IND-enabling and clinical trial studies in the US, in association with the US Government agency.
  4. 04

    Colon Cancer

    View the indication
    • Phase I/IIa clinical trial approved by DCGI.
    • Trial ongoing with Tata Memorial Hospital, Mumbai.
  5. 05

    Pancreatic Cancer

    View the indication
    • Phase I/IIa clinical trial approved by DCGI.
    • Clinical trial ongoing with Tata Memorial Hospital, Mumbai.
    • Phase II clinical trials completed with significant results.
    • DCGI approval received to conduct a Phase III clinical trial.
    • Significant findings in patients with severe COVID-19 with Lung Inflammation.
    • Powerful anti-inflammatory and immunomodulatory mechanism identified.
    • Trial paused following the emergence of the Omicron variant.
  6. 07

    Other therapeutic programmes

    View the indication
    • Overall six new chemical entities (NCEs) targeting 14 serious and unmet medical indications.
    • Additional programmes targeting Brain Cancer, Lung Cancer, Liver Cancer, Triple-Resistant Breast Cancer, Stomach Cancer and Pancreatitis are ready to move on to IND studies.

Stage of development

Every Molecules Grouped By Thelaputic Areas, with the biological action and stage for each indication

Immune & inflammation3 programmes

  • PNB-001

    COVID-19 Lung InflammationCCK ligand, lymphokine

  • PNB-001

    Ulcerative ColitisCCK ligand, lymphokine, T-cell activation

  • PNB-001

    Crohn's DiseaseCCK ligand, lymphokine, T-cell activation

Graph of the stage of development of each Immune & inflammation programme. Horizontal axis: clinical development stage, from Preclinical to Phase 3. Vertical axis: molecule and indication. Each marker opens the programme's indication, biological action, stage and status.

Oncology5 programmes

  • PNB-028

    Pancreatic CancerCCK inhibition via the CCK-C receptor

  • PNB-028

    Colon CancerCCK inhibition via the CCK-C receptor

  • PNB-101

    Lung CancerCCK-B pathway inhibition

  • PNB-101

    Liver CancerCCK-B pathway inhibition

  • PNB-291

    Brain CancerPan-CCK blocker

Graph of the stage of development of each Oncology programme. Horizontal axis: clinical development stage, from Preclinical to Phase 3. Vertical axis: molecule and indication. Each marker opens the programme's indication, biological action, stage and status.

CNS & addiction3 programmes

  • PNB-001

    DementiaCCK-mediated release of acetylcholine (ACh)

  • PNB-081

    Opiate ManagementCCK-A antagonist

  • PNB-091

    Cocaine AddictionPan-CCK blocker

Graph of the stage of development of each CNS & addiction programme. Horizontal axis: clinical development stage, from Preclinical to Phase 3. Vertical axis: molecule and indication. Each marker opens the programme's indication, biological action, stage and status.

Metabolic Diseases3 programmes

  • PNB-001

    Type 2 DiabetesCCK-mediated blood glucose reduction; restoration of pancreatic cells

  • PNB-028

    PancreatitisInhibition of pancreatic enzymes

  • PNB-081

    ObesityCCK-mediated reduction of food intake

Graph of the stage of development of each Metabolic Diseases programme. Horizontal axis: clinical development stage, from Preclinical to Phase 3. Vertical axis: molecule and indication. Each marker opens the programme's indication, biological action, stage and status.

Molecules and indications

Each molecule acts on CCK receptors in a different way, so several reach more than one disease.

Select a molecule to isolate its indications.

All 14 molecule–indication links are shown.

Molecule profiles

Select a molecule to see the indications it is being developed for. Each indication opens its study: target, preclinical findings, development and clinical status.

5indications

Front-runner

Clinical · Phase 1 and Phase 2 completed

3indications

Second clinical molecule

Clinical · Phase 1/2a ongoing

2indications

Metabolic & opiate programme

Preclinical completed · IND ready

2indications

Targeted oncology

IND ready

1indication

Pan-CCK oncology

IND ready

1indication

Addiction research with NIDA

IND ready

PNB-0015 indications

CNS & addiction

PNB-0283 indications

Metabolic Diseases

PNB-0812 indications

Metabolic Diseases

CNS & addiction

PNB-1012 indications

PNB-2911 indication

PNB-0911 indication

CNS & addiction

Interested in a programme?

PNB Vesper welcomes discussions on clinical development, licensing, co-development and investment for any molecule in the pipeline.